This is a placebo-controlled, double blind, crossover study to evaluate the efficacy and
safety of KHK6188 in postherpetic neuralgia when administered orally for 2 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.